<DOC>
	<DOCNO>NCT02358096</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ASP8232 reduce Urinary Albumin Creatinine Ratio ( UACR ) subject Type 2 Diabetes Mellitus ( T2DM ) Chronic Kidney Disease ( CKD ) 12 week compare placebo .</brief_summary>
	<brief_title>A Study Evaluate ASP8232 Add-On Therapy Angiotensin Converting Enzyme Inhibitor ( ACEi ) Angiotensin Receptor Blocker ( ARB ) Reducing Albuminuria Patients With Type 2 Diabetes Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Subject must estimate glomerular filtration rate ( eGFR ) ) &gt; =25 &lt; 75 ml/min/1.73m2 . Subject must document diagnosis T2DM receive antidiabetic medication ( oral and/or parenteral ) least 1 year prior screen Subject 's glycated hemoglobin ( HbA1c ) level &lt; 11.0 % ( &lt; 97 mmol/mol ) screening . Subject stable therapy angiotensinconvertingenzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) least 3 month prior screen . Subject receive antihypertensive treatment , noninsulin antidiabetic agent and/or vitamin D receptor activator screen need stable therapy least 3 month prior screen . Subjects insulin therapy may insulin type/dose/schedule adjust even 3 month prior screen . If subject subject specific dietary intervention stable past 3 month prior screen visit . Subject 's UACR ≥ 200 ≤ 3000 mg/g first morning void ( FMV ) sample screen AND geometric mean UACR FMV sample visit 4 visit 5 ≥ 200 ≤ 3000 mg/g AND UACR least 3 FMV sample visit 4 visit 5 ≥ 200 mg/g . Subject , previously receive , renal replacement therapy ( e.g . dialysis kidney transplantation ) . Subject obstructive uropathy cause renal impairment relate parenchymal renal disorder and/or disease kidney ; subject currently past renal disease secondary malignancy . Subject 's renal impairment and/or albuminuria consider origin Diabetic Kidney Disease . Subject know ( auto ) immune disorder and/or receive immunosuppression 2 week , cumulatively , within 12 week prior screen anticipate need immunosuppressive therapy study . Subject active urinary tract infection require treatment clinically significant infection time screen randomization Subject diagnose type 1 diabetes mellitus diabetes mellitus unclear etiology . Subject sit systolic blood pressure ( SBP ) &lt; 90 &gt; 160 mmHg and/or diastolic blood pressure ( DBP ) &gt; 90 mmHg screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>ASP8232</keyword>
</DOC>